Abstract
The present analysis focuses on real-world data of Everolimus-Exemestane in advanced HR+ve, HER2-ve elderly breast cancer patients (aged 65 years) included in the EVA study, with unique findings in those aged 70 years. Data are collected from clinical records and analysed according to age cut-off (< 65 years; 65 - 69 years and {greater than or equal to} 70 years). Relationship of analyzed variables with response were tested by mean of a Mantel-Haenszel chi square test. Time to event analysis was described by Kaplan Meier approach and association with baseline characteristics was analysed by stratified log-rank test and proportional hazard model. From July 2013 to December 2015, the EVA study enrolled overall 404 pts. 154 patients out of 404 (38,1%) were aged {greater than or equal to} 65 years, of whom 87 were {greater than or equal to} 70 years. Median duration of EVE treatment was 28.5 weeks (95% CI 19.0 - 33.8) in patients aged 65-69 years and 24,4 weeks (95% CI 19,2 - 33,2) in those aged {greater than or equal to} 70 years. Fewer patients aged 65 years received the highest EVE Dose-Intensity (>7.5 mg/day) in comparison to younger patients (49,6% vs. 66,8%). Grade 3-4 toxicities occurred to 55 patients (35,7%), mainly stomat...Continue Reading
References
Dec 1, 1995·Journal of Clinical Epidemiology·P PeduzziT R Holford
Jul 1, 2008·Journal of Oncology Practice·Michele BascheJohn F Steiner
Dec 14, 2011·The New England Journal of Medicine·José BaselgaGabriel N Hortobagyi
Feb 3, 2012·European Urology·Camillo PortaRobert J Motzer
Apr 4, 2012·The Lancet Oncology·Laura BiganzoliRiccardo Audisio
Nov 26, 2013·Clinical Breast Cancer·Kathleen I PritchardMichael Gnant
Mar 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H S RugoH A Burris
Aug 1, 2014·CMAJ Open·Ashley DavidsonScott Tyldesley
Jul 1, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G JerusalemP Conte
Nov 3, 2016·The New England Journal of Medicine·Gabriel N HortobagyiJoyce O'Shaughnessy
Dec 14, 2016·The New England Journal of Medicine·Richard S FinnDennis J Slamon
Dec 20, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rachel A FreedmanArti Hurria
Mar 21, 2017·The Lancet Oncology·Hope S RugoJennifer K Litton
Jul 18, 2017·The Breast : Official Journal of the European Society of Mastology·M E CazzanigaUNKNOWN EVA Study Group
Nov 6, 2017·Breast Cancer Research and Treatment·Rachel A Freedman, Sara M Tolaney
Apr 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H S RugoH A Burris